Preferred Label : regorafenib;

MeSH note : has antineoplastic activity; structure in first source;

CISMeF synonym : BAY 73-4506; Stivarga;

MeSH synonym : 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide;

MeSH hyponym : BAY73-4506; BAY-73-4506;

Is substance : O;

UNII : 24T2A1DOYB;

InChIKey : FNHKPVJBJVTLMP-UHFFFAOYSA-N;

Details


Main resources

You can consult :


http://conseil-scientifique.public.lu/fr/publications/oncologie/regorafenib-mise-a-jour-2018.html
2018
false
false
true
Luxembourg
French
guidelines for drug use
adult
regorafenib
regorafenib
administration, oral
colorectal neoplasms
neoplasm metastasis
Metastatic colorectal cancer
gastrointestinal stromal tumors
disease progression
carcinoma, hepatocellular
protein kinase inhibitors
antineoplastic agents
survival analysis
phenylurea compounds
pyridines

---
Extension d'indication
https://www.has-sante.fr/portail/jcms/c_2825855/fr/stivarga-chc
2018
false
France
French
regorafenib
regorafenib
regorafenib
administration, oral
treatment outcome
insurance, health, reimbursement
adult
antineoplastic agents
antineoplastic agents
evaluation of the transparency committee
carcinoma, hepatocellular
phenylurea compounds
pyridines
phenylurea compounds
pyridines

---
http://www.has-sante.fr/portail/jcms/c_2566483/fr/stivarga
http://www.has-sante.fr/portail/jcms/c_2566483/fr/stivarga-regorafenib-inhibiteur-de-proteine-kinase
2015
false
France
French
regorafenib
regorafenib
regorafenib
administration, oral
treatment outcome
insurance, health, reimbursement
adult
neoplasm metastasis
antineoplastic agents
antineoplastic agents
Progression-Free survival
evaluation of the transparency committee
Unresectable Malignant Neoplasm
gastrointestinal stromal tumors
guidelines for drug use
protein kinase inhibitors
protein kinase inhibitors
disease-free survival
phenylurea compounds
pyridines
phenylurea compounds
pyridines

---
http://www.has-sante.fr/portail/jcms/c_1743045/fr/stivarga
2014
false
France
French
regorafenib
regorafenib
regorafenib
administration, oral
treatment outcome
insurance, health, reimbursement
adult
neoplasm metastasis
colorectal neoplasms
antineoplastic agents
antineoplastic agents
Progression-Free survival
evaluation of the transparency committee
disease-free survival
phenylurea compounds
pyridines
phenylurea compounds
pyridines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=69548508
2014
summary of product characteristics
regorafenib
tablets
regorafenib

---
https://www.ema.europa.eu/medicines/human/EPAR/Stivarga
2013
false
United Kingdom
English
French
regorafenib
regorafenib
regorafenib
drug approval
europe
treatment outcome
colorectal neoplasms
neoplasm metastasis
antineoplastic agents
antineoplastic agents
adult
protein kinase inhibitors
protein kinase inhibitors
summary of product characteristics
package leaflet
drug evaluation
syndication feed
administration, oral
aged
continuity of patient care
drug interactions
pregnancy
breast feeding
fertility
survival analysis
drug evaluation, preclinical
phenylurea compounds
phenylurea compounds
pyridines
pyridines

---
Nous contacter.
18/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.